We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In 2017, Pfizer’s board of directors was throwing money at CEO Ian Read to persuade him to stay at least through March of this year. His total compensation jumped more than 60% to $27.9 million, though a lot of that came from equity-based incentives.